HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stada Strikes Deal To Launch ViruProtect In Nordics

Executive Summary

Stada to launch innovative common cold spray ViruProtect in four Nordic markets in 2021 after striking a new agreement with Sweden's Enzymatica.

You may also be interested in...



EU Business Round-Up: HRA Pharma Strikes Spain Deal, Enzymatica Expands Production

Latest EU business news: HRA Pharma strikes distribution deal with Vemedia for Spain; and Enzymatica increases ColdZyme production to meet growing demand.

Stada Takes ViruProtect To Russia And Beyond

Germany's Stada has expanded its deal with Enymatica to take the latter's ViruProtect common cold brand into Russia, the CIS and beyond.

Stada’s ViruProtect Could Prevent COVID Infection, In Vitro Study Shows

A recent in vitro study shows that Enzymatica's ColdZyme throat spray – the basis for Stada's ViruProtect in Belgium and Austria – could offer a protective barrier against harmful viruses such as SARS-CoV-2.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel